BEVACIZUMAB AND PLATINUM-BASED CHEMOTHERAPY IN RELAPSED OVARIAN CANCER TREATMENT

被引：0
|
作者：
Davidenko, I. [1 ]
Kazantseva, M. [1 ]
Porhanova, N. [1 ]
Potemin, S. [1 ]
Oganyan, M. [1 ]
Syrota, L. [1 ]
Shmatkova, V. [1 ]
机构：
[1] Reg Oncol Ctr, Krasnodar, Russia
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab combined with platinum-based chemotherapy in primary or relapsed ovarian cancer patients: Meta-analysis and literature to review
    Tauseef, Abubakar
    Zafar, Maryam
    Abodunrin, Faith
    Siddiqui, Sameed A. H.
    Millner, Paul
    Khan, Saber M.
    Teplitsky, Ella
    Masih, Durva
    Mirza, Muazzam
    Mirza, Mohsin
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (11) : 2797 - 2804
  • [2] Bevacizumab combined with platinum-based chemotherapy in patients with primary or relapsed ovarian cancer: Meta-analysis and literature review.
    Abodunrin, Faith
    Tauseef, Abubakar
    Silberstein, Peter T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2)
    Ledermann, JA
    BRITISH JOURNAL OF CANCER, 2003, 88 : S9 - S9
  • [4] Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer
    Markman, Maurie
    GYNECOLOGIC ONCOLOGY, 2007, 106 (01) : 273 - 274
  • [5] Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
    Yang, Ling
    Xie, Hong-Jian
    Li, Ying-Ying
    Wang, Xia
    Liu, Xing-Xin
    Mai, Jia
    ONCOLOGY REPORTS, 2022, 47 (04)
  • [6] Risk of leukemia after platinum-based chemotherapy for ovarian cancer
    Travis, LB
    Holowaty, EJ
    Bergfeldt, K
    Lynch, CF
    Kohler, BA
    Wiklund, T
    Curtis, RE
    Hall, P
    Andersson, M
    Pukkala, E
    Sturgeon, J
    Stovall, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (05): : 351 - 357
  • [7] Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:: the ICON4/AGO-OVAR-2.2 trial
    Parmar, MKB
    Ledermann, JA
    Colombo, N
    du Bois, A
    Delaloye, JF
    Kristensen, GB
    Wheeler, S
    Swart, AM
    Qian, W
    Torri, V
    Floriani, I
    Jayson, G
    Lamont, A
    Tropé, C
    Lederman, JA
    Parmar, MKB
    Mangioni, C
    Torri, V
    Sandercock, J
    Dubois, A
    LANCET, 2003, 361 (9375): : 2099 - 2106
  • [8] Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer
    Milczek, Tomasz
    Klasa-Mazurkiewicz, Dagmara
    Emerich, Janusz
    Kobierski, Juliusz
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2009, 88 (04) : 463 - 467
  • [9] VIMENTINE AS A PREDICTIVE MARKER OF PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER PATIENTS
    Bogush, T.
    Dudko, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1408 - 1408
  • [10] Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy
    Neeser, Kurt
    O'Neil, William M.
    Stern, Lee
    Harrow, Brooke
    Travers, Karin
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (08) : 577 - 587
12345